Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

About Dimebon

Dimebon is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease and in clinical development for Huntington disease. In preclinical models of Alzheimer's disease and Huntington disease explored thus far, dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The dimebon mechanism is thought to be distinct from that of currently available Alzheimer's disease medications.

In addition to CONNECTION, dimebon is being studied in the 12-month Phase 3 CONCERT trial, which is evaluating the efficacy of dimebon when added to ongoing treatment with donepezil (Aricept(R)) in patients with mild-to-moderate Alzheimer's disease, and in a Phase 3 safety study. Two Phase 3 studies in moderate-to-severe Alzheimer's disease are also planned to start this year.

In Huntington disease, a Phase 2 study has been completed. Medivation and Pfizer expect to initiate a Phase 3 trial this year to evaluate the potential benefits of dimebon on cognition in patients with Huntington disease.

About Alzheimer's Disease

Alzheimer's disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Pearl's Premium Ultra Low ... drought tolerant grass seed this week with the release ... announcement coincides with the fact that it is time ... many believe. , As of the date 6/4/13, ... reviews by industry experts and the media including: ...
(Date:9/22/2014)... tiny cell fragments whose job it is to stop ... nucleus. But they can "feel" the physical environment around ... , Platelets respond to surfaces with greater stiffness by ... on" other platelets and other components of the clotting ... we give them credit for, in that they are ...
(Date:9/22/2014)... create a highly sensitive chemical sensor based on the ... electronic properties that the researchers were able to exploit ... times. , The study is available online in advance ... Salehi- Khojin, asst professor of mechanical and industrial engineering ... Bijandra Kumar, post doc where they are doing research ...
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
Breaking Biology Technology:Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... Without clear leadership and more transparency in federal risk ... a happy accident, rather than a foregone conclusion, says ... Project on Emerging Nanotechnologies (PEN). This sentiment was voiced ... Science & Technology Committees hearing on the National Nanotechnology ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), today ... Capital Market listing requirements. On April,16, 2008, the ... that it has regained compliance with Nasdaq,Marketplace Rule ... Company,s,common stock has been equal to or in ...
... Md., April 16 The Board of Managers ... Dr. Danong Chen has,been elected as the new ... previously the President and CEO of Tanox Inc., ... Genentech in 2007.,Previously Dr. Chen was Vice-President of ...
Cached Biology Technology:Limited transparency in federal nanotech research may hamper development 2Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements 2Danong Chen appointed CEO of Theranostics Health 2
(Date:9/21/2014)... emissions, the main contributor to global warming, are set to ... 40 billion tonnes. , The 2.5 per cent projected rise ... Project, which is co-led in the UK by researchers at ... of East Anglia and the College of Engineering, Mathematics and ... ahead of the New York Climate Summit, where world leaders ...
(Date:9/21/2014)... has developed a protein therapy that disrupts the process ... tumor sites, travel through the blood stream and start ... process, known as metastasis, can cause cancer to spread ... who succumb to cancer fall prey to metastatic forms ... of bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... the sake of fairness per se but in order ... Frans de Waal, PhD, and Sarah Brosnan, PhD, co-authors ... is defined as a negative reaction to unequal outcomes. ... , Their conclusion comes after the co-authors reviewed more ... it is the evolution of forestalling partner dissatisfaction with ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... have identified some of the very earliest genetic changes involved ... into a new strain of mouse that develops the disease ... discoveries, reported in the August 1 issue of Cancer Research, ... that could be offered at the very first signs of ...
... using pathogenic fungi as model systems for understanding fungal ... that offers insight into how carbon dioxide (CO2) governs ... in different environments and invade the human body, and ... metabolism utilize evolutionarily conserved enzymes to control the growth ...
... novel application of an fMRI (functional magnetic resonance ... School of Medicine have, for the first time, ... a healthy human brain. , Their work, performed ... neuro-imaging marker of psychological stress -- which will ...
Cached Biology News:Building a better mouse model of lung cancer: FHIT counts 2Building a better mouse model of lung cancer: FHIT counts 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3Research Permits First-Ever Visualization of Psychological Stress in the Human Brain 2
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
...
Hybridization Buffer 3.6 ml...
Biology Products: